Table 1. Results of patients with positive genetics for periodic paralysis and/or positive long exercise test.

Variables	Genetics positive LET positive	Genetics positive LET negative	Genetics negative LET positive	p value	Statistical test
Patients	n = 32	n = 13	n = 22	N/A	N/A
Age in years	36.6±14.2 (15-64)	44.4±15.4 (18-77)	36.4±12.8 (17-63)	0.197	ANOVA
Gender M/F (M:F ratio)	26/6 (4.3 : 1)	8/5 (1.6 : 1)	21/1 (21 : 1)	0.040	Fisher
No of patients on PP medication (%)	20 (62.5%)	3 (23.1%)	2 (9.1%)
Largest CMAP in mV	8.1±1.8* (4.2-11.6)	9.1±1.8 (4.4-12.8)	10.5±2.1* (6.0-15.2)	<0.001	ANOVA
Increment in %	28.4±26.4 (-11-119)	11.8±15.1 (-13-48)	28.1±14.9 (4-58)	0.017	Kruskal-Wallis
Decrement from peak in %	55.0±11.6 (33-80)	28.7±6.4 (15-39)	51.3±8.4 (42-68)	N/A†	N/A
Decrement from baseline in %	41.8±19.1 (-12-81)	2O.1±11.2 (0-38)	37.9±12.2 (12-57)	N/A†	N/A
Time to 40% decrement in minutes	21.4±13.0 ‡ (4-54)	N/A	28.7±12.6 (3-46)	0.051	t

Continuous quantitative data were plotted as mean ± standard deviation (range).

^*Groups with statistically significant differences

^†Statistical analysis was not performed as group allocation was according to peak decrement.

^‡4/32 patients incorporated after SET calculations could not be included as a 40% decrement was not achieved during LET.

PP: periodic paralysis; CMAP: compound muscle action potential; F: female; LET: long exercise test; M: male; N/A: not applicable